Pharmaco-economic aspects of inhibitor treatment

European Journal of Haematology

Volumn 61, Issue SUPPL.63, 1998, Pages 24-27

  Goudemand, Jenny ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Inhibitor costs; Pharmaco economics; RFVlla

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; ANTIBODY; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; AGED; BLEEDING; CHILD; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DOSE RESPONSE; HEALTH CARE QUALITY; HEMOPHILIA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOGICAL TOLERANCE; INHIBITION KINETICS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; ARTICLE; BLOOD; DRUG COST; DRUG SELF ADMINISTRATION; ECONOMICS; HEMOPHILIA A; IMMUNOLOGY;

ANTIBODIES; DRUG COSTS; FACTOR IX; FACTOR VIIA; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; RECOMBINANT PROTEINS; SELF ADMINISTRATION;

EID: 0032252398     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1998.tb01107.x     Document Type: Article

References (7)

1. MACIKB G. Treatment of Factor VIII inhibitors: products and strategies. Semin Thromb Hemost 1993;19:13-24.
2. LIPTON RA. The economics of Factor VIII inhibitor treatment. Semin Hematol 1994;31(suppl 2):37-38.
3. ROBERTS HR. Hemophilia with inhibitors: therapeutic options (editorial). N Engl J Med 1981;305:757-758.
4. Szucs TD, OWNER A, SCHRAMM W. Socioeconomic impact of haemophilia care. Haemophilia 1996;2:211-217.
5. PERRY MC. Mortality and morbidity in hemophilia. Missouri Med 1984;81133-135.
6. VERMYLE J, PEERLINCK K. Optimal care of inhibitor patients during surgery. Eur J Haematol 1998;61(suppl63):15-17.
7. ROSS-DEGNAN D, SOUMERAI SB, AVORN J, BOHN RL, BRIGHT R, ALEDORT LM. Hemophilia home treatment. Economic analysis and implications for healthy policy. Int J Tech Asses Health Care 1995;11:327-344.